4D Molecular Therapeutics (FDMT) Change in Acquisitions & Divestments (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $102.4 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 38.56% year-over-year to $102.4 million in Q1 2026; TTM through Mar 2026 was $286.1 million, a 10.83% decrease from a year earlier, with the FY2025 full-year figure at $350.4 million, up 107.33% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $102.4 million, up from $49.2 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for FDMT reached as high as $205.3 million in Q3 2022 and fell as low as -$135.2 million in Q4 2022.
• Historically, Change in Acquisitions & Divestments has averaged $55.5 million across 5 years, with a median of $55.5 million in 2023.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 2803.88% in 2022 and soared 1027.88% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at -$135.2 million in 2022, then soared by 121.09% to $28.5 million in 2023, then jumped by 130.72% to $65.8 million in 2024, then fell by 25.24% to $49.2 million in 2025, then surged by 108.19% to $102.4 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $102.4 million in Q1 2026, $49.2 million in Q4 2025, and $32.9 million in Q3 2025.